ACADIA Pharmaceuticals Inc Positive Top-line Results from Phase Corporate Call
Conference Call ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc Conference call or earnings call will be held on Oct 31, 2018 via an 800 number (toll-free). During the earnings conference call's session ACADIA Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact ACADIA Pharmaceuticals Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. We have a portfolio of product opportunities led by our novel drug candidate, NUPLAZIDTM (pimavanserin), for which we have reported positive Phase III pivotal trial results in Parkinson's disease psychosis, or PDP, and which has the potential to be the first drug approved in the United States for this condition. NUPLAZID is a selective serotonin inverse agonist, or SSIA, preferentially targeting 5-HT2A receptors. Through this novel mechanism, NUPLAZID has demonstrated significant efficacy in Parkinson's disease psychosis in our Phase III pivotal trial and has the potential to avoid many of the debilitating side effects of existing antipsychotics, none of which are approved for use in PDP patients. We hold worldwide commercialization rights to pimavanserin.Read more Conference Call